Familial hypercholesterolemia: A missed opportunity in preventive medicine

Nature Clinical Practice Cardiovascular Medicine

Volumn 4, Issue 8, 2007, Pages 404-405

  Watts, Gerald F ^a   Lewis, Barry ^b   Sullivan, David R ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HEALTH CARE SYSTEM; HUMAN; INHERITANCE; PATHOPHYSIOLOGY; PHENOTYPE; PRESCRIPTION; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

CORONARY ARTERIOSCLEROSIS; FEMALE; GENOTYPE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INCIDENCE; LIFE STYLE; MALE; MASS SCREENING; MUTATION; PREVALENCE; PREVENTIVE MEDICINE; PROGNOSIS; RISK ASSESSMENT; WORLD HEALTH ORGANIZATION;

EID: 34547544829     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0941     Document Type: Review

References (11)

1. World Health Organisation, Human Genetics Programme (1997) Familial Hypercholesterolemia (FH): Report of a WHO Consultation, Paris, 3 October 1997. Geneva, Switzerland
2. Marks D et al. (2003) A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168: 1-14
3. Ceveira F for the International Panel on Management of Familial Hypercholesterolemia (2004) Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 173: 55-68
4. EUROASPIRE II Study Group (2001) Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22: 554-572
5. Pearson TA (2007) The prevention of cardiovascular disease: Have we really made progress? Health Aff (Millwood) 26: 49-60
6. Marks D et al. (2002) Cost-effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 324: 1303-1308
7. Leren TP (2004) Cascade genetic screening for familial hypercholesterolemia. Clin Genet 66: 483-487
8. Agard A et al. (2005) Familial hypercholesterolemia: Ethical, practical and psychological problems from the perspective of patients. Patient Educ Couns 57: 162-167
9. Van Meade MC et al. (2003) Quality of life in a family based genetic cascade screening programme for familial hypercholesterolaemia: a longitudinal study among participants. J Med Genet 40: e3-e8
10. Rodenburg J et al. (2004) Familial hypercholesterolemia in children. Curr Opin Lipidol 15: 405-411
11. Kavey RE et al. (2006) Cardiovascular risk reduction in high risk pediatric patients: A scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics. Circulation 114: 2710-2738